FGENFIBROGEN INC

Nasdaq fibrogen.com


$ 0.41 $ 0.04 (9.88 %)    

Tuesday, 20-Aug-2024 15:58:40 EDT
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.38 (0.39 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 0.415
$ 0.39
$ 0.40 x 600
$ 0.42 x 600
$ 0.39 - $ 0.43
$ 0.33 - $ 2.93
2,605,220
na
41.43M
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-06-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-06-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 02-27-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 02-27-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-01-2017 12-31-2016 10-K
32 11-08-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-13-2015 06-30-2015 10-Q
38 05-12-2015 03-31-2015 10-Q
39 03-26-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fibrogen-q2-2024-gaap-eps-016-beats-026-estimate-sales-50641m-beat-34661m-estimate

FibroGen (NASDAQ:FGEN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.26) by 3...

 fibrogen-announces-topline-results-from-two-late-stage-pamrevlumab-pancreatic-cancer-studies-pamrevlumab-arm-of-precision-promisesm-study-in-metastatic-pancreatic-cancer-did-not-meet-primary-endpoint

Pamrevlumab arm of the Precision PromiseSM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Can...

 whats-going-on-with-fibrogen-stock-tuesday

FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational...

 fibrogen-stock-is-surging-after-the-bell-whats-going-on

FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investiga...

Core News & Articles

FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combi...

 fibrogen-shares-climb-on-strong-q1-sales

FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION